Download PDFPDF

Original research
Second-generation antipsychotics and the risk of chronic kidney disease: a population-based case-control study
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Second-generation antipsychotics and chronic kidney disease: a risk assessment

    Højlund et al. conducted a 1:4 matching case-control study to examine the association between use of second-generation antipsychotics (SGA) and the risk of chronic kidney disease (CKD) (1). They defined CKD as an estimated glomerular filtration rate below 60 mL/min/1.73 m2 for 3 months or more. The adjusted odds ratios (ORs) (95% confidence intervals [CIs]) of ever and current SGA users for the risk of CKD were 1.24(1.12 to 1.37) and 1.26 (1.12 to 1.42), although there was no dose-response relationship. In addition, the adjusted ORs (95% CIs) of short-term and long-term SGA users for the risk of CKD were 1.22 (1.01 to 1.48) and 1.45 (1.19 to 1.76), respectively. Furthermore, clozapine presented the highest risk of CKD, and aripiprazole presented no significant risk of CKD. I have a comment about their study with special reference for the psychiatric diseases.

    Wang et al. conducted a risk assessment of CKD between patients with schizophrenia using first and second-generation antipsychotics (2). They defined CKD as a kidney damage as albumin-to-creatinine ratio >30 mg/g or glomerular filtration rate below 60 mL/min/1.73 m2 for 3 months or more. The risks for CKD were significantly higher in patients with SGA, although the risk did not increase as the patients used SGA for longer period. As the information in the risk of CKD in patients with SGA is limited, further studies are recommended by specifying the psychiatric diseases and CKD-related comorbidities.


    Show More
    Conflict of Interest:
    None declared.